BIODEXA PHARMACEUTICALS PLC

• ⚠

  Material uncertainty over going concern

  This requirement for additional financing in the short term represents a material uncertainty that may cast significant doubt upon the Group and Parent Company's ability to continue as a going concern.

1. BIODEXA PHARMACEUTICALS PLC 2023-03-27 → present
2. MIDATECH PHARMA PLC 2014-11-27 → 2023-03-27
3. MIDATECH PHARMA LIMITED 2014-09-12 → 2014-11-27

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

PKF Littlejohn LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“This requirement for additional financing in the short term represents a material uncertainty that may cast significant doubt upon the Group and Parent Company's ability to continue as a going concern.”

Group structure

1. BIODEXA PHARMACEUTICALS PLC · parent
   1. Biodexa Pharmaceuticals PLC · Ultimate holding company
   2. Biodexa Australia PTY Limited 100% · Australia · Trading company
   3. Biodexa Limited 100% · Cardiff · Trading company
   4. Biodexa Pharmaceuticals (Wales) Limited 100% · Cardiff · Trading company
   5. Haaland UK Limited 100% · Cardiff · Dormant
   6. PharMida AG 100% · Switzerland · Dormant

Significant events

• “In May 2024, we entered into agreements with certain investors that were holders of 1,572,674 of our outstanding Series E warrants exercisable for $2.20 per Depositary Share and an aggregate of 2,463,477 of our Series F warrants exercisable for $2.20 per Depositary Share, or Series F Warrants. The holders agreed to exercise the Series E Warrants and Series F Warrants, as applicable, at a reduced exercise price of $1.50 per Depositary Share.”
• “In July 2024, we closed a Registered Direct Offering and Private Placement with certain institutional investors for the sale of (i) an aggregate of 5,050,808 Depositary Shares, and (ii) an aggregate of 278,975 pre-funded warrants exercisable for Depositary Shares at a price per Depositary Share of $0.94, and a price per Pre-Funded Warrant of $0.9399.”
• “In December 2024 we issued an unsecured Promissory Note to C/M Capital Master Fund LP in the principal amount of $600,000 at a 10% original issue discount.”
• “In August 2024, we received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying us that NASDAQ had determined to delist our securities from the NASDAQ Capital Market because our securities had a closing bid price below $1.00 for 30 consecutive business days. We requested a hearing...”
• “On 7 November 2024, we were notified that the Hearings Panel had determined that we had regained compliance with the minimum bid price requirement.”
• “On 4 October 2024 the Company effected a change in the ratio of the Company's Ordinary Shares from each ADS representing 400 Ordinary Shares to each ADS representing 10,000 Ordinary Shares.”
• “On 17 January 2025, we entered into an ELOC with C/M pursuant to which we have the right, but not the obligation, to sell to C/M, and C/M is obligated to purchase, up to $35.0 million of newly issued ADSs for a period of 36 months from Commencement Date.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

15

last 24 months

Officers appointed

2

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -100%

  £381,000 → £0

  lowest in 3 filed years

• Cash

  -72%

  £5,971,000 → £1,669,000

  lowest in 3 filed years

• Net assets

  +77.9%

  £4,678,000 → £8,322,000

  highest in 3 filed years

• Employees

  -38.1%

  21 → 13

  lowest in 3 filed years

• Operating profit

  -14.8%

  -£8,014,000 → -£9,199,000

  lowest in 3 filed years

• Profit before tax

  +20.1%

  -£7,485,000 → -£5,979,000

  highest in 3 filed years

• Wages

  -6.5%

  £1,708,000 → £1,597,000

  lowest in 3 filed years

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers